CLEC4M and STXBP5 gene variations contribute to von Willebrand factor level variation in von Willebrand disease

Journal of Thrombosis and Haemostasis

Volumn 13, Issue 6, 2015, Pages 956-966

  Sanders, Y V ^a   van der Bom, J G ^b,c   Isaacs, A ^a   Cnossen, M H ^a,d   de Maat, M P M ^a   Laros van Gorkom, B A P ^e   Fijnvandraat, K ^f,i   Meijer, K ^g   van Duijn, C M ^a   Mauser Bunschoten, E P ^h,o,p,q,r   Eikenboom, J ^b   Leebeek, F W G ^a   Coppens, M ⁱ   Kors, A ^j   de Meris, J ^k   Nijziel, M R ^l   Tamminga, R Y J ^g   Ypma, P F ^m   Smiers, F J W ^b   Granzen, B ⁿ   Hamulyak, K ⁿ   Brons, P ^e   more..

^a ERASMUS MEDICAL CENTER   (Netherlands)

^b LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

^c SANQUIN RESEARCH   (Netherlands)

^d SOPHIA CHILDREN S HOSPITAL   (Netherlands)

^e RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

^f EMMA CHILDREN S HOSPITAL   (Netherlands)

^g UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

^h UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

ⁱ ACADEMIC MEDICAL CENTER   (Netherlands)

^j VU UNIVERSITY MEDICAL CENTER   (Netherlands)

^k Netherlands Hemophilia Society   (Netherlands)

^l MÁXIMA MEDICAL CENTER   (Netherlands)

^m HAGA HOSPITAL   (Netherlands)

ⁿ MAASTRICHT UNIVERSITY MEDICAL CENTER   (Netherlands)

^o UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

^p AMPHIA HOSPITAL   (Netherlands)

^q CATHARINA HOSPITAL   (Netherlands)

^r Infection and Immunology   (Netherlands)

more..

Author keywords

CLEC4M protein, human; Polymorphism, single nucleotide; STXBP5 protein, human; Von Willebrand disease; Von Willebrand factor

Indexed keywords

VON WILLEBRAND FACTOR; BIOLOGICAL MARKER; CELL ADHESION MOLECULE; CELL SURFACE RECEPTOR; CLEC4M PROTEIN, HUMAN; LECTIN; NERVE PROTEIN; STXBP5 PROTEIN, HUMAN; SYNAPTOBREVIN;

ABO GENE; ADOLESCENT; ADULT; AGED; ALLELE; ARTICLE; BLOOD GROUP ABO SYSTEM; CHILD; CLEC4M GENE; CONTROLLED STUDY; CROSS-SECTIONAL STUDY; FEMALE; GENE; GENE FREQUENCY; GENETIC ASSOCIATION; GENETIC VARIABILITY; HETEROZYGOTE; HUMAN; MAJOR CLINICAL STUDY; MALE; NETHERLANDS; PHENOTYPE; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; SCARA5 GENE; SINGLE NUCLEOTIDE POLYMORPHISM; STAB2 GENE; STX2 GENE; STXBP5 GENE; TC2N GENE; VON WILLEBRAND DISEASE; VWF GENE; BLEEDING; BLOOD; BLOOD CLOTTING; BLOOD CLOTTING TEST; CLINICAL TRIAL; GENETIC ASSOCIATION STUDY; GENETIC PREDISPOSITION; GENETICS; INFANT; MIDDLE AGED; MOLECULAR DIAGNOSIS; MULTICENTER STUDY; PRESCHOOL CHILD; RISK FACTOR; VERY ELDERLY; VON WILLEBRAND DISEASE, TYPE 1; VON WILLEBRAND DISEASE, TYPE 2; YOUNG ADULT;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; BIOMARKERS; BLOOD COAGULATION; BLOOD COAGULATION TESTS; CELL ADHESION MOLECULES; CHILD; CHILD, PRESCHOOL; CROSS-SECTIONAL STUDIES; FEMALE; GENE FREQUENCY; GENETIC ASSOCIATION STUDIES; GENETIC PREDISPOSITION TO DISEASE; HEMORRHAGE; HUMANS; INFANT; LECTINS, C-TYPE; MALE; MIDDLE AGED; MOLECULAR DIAGNOSTIC TECHNIQUES; NERVE TISSUE PROTEINS; NETHERLANDS; PHENOTYPE; POLYMORPHISM, SINGLE NUCLEOTIDE; R-SNARE PROTEINS; RECEPTORS, CELL SURFACE; RISK FACTORS; VON WILLEBRAND DISEASE, TYPE 1; VON WILLEBRAND DISEASE, TYPE 2; VON WILLEBRAND FACTOR; YOUNG ADULT;

EID: 84930180243     PISSN: 15387933     EISSN: 15387836     Source Type: Journal    
DOI: 10.1111/jth.12927     Document Type: Article

References (33)

1. James PD, Lillicrap D. von Willebrand disease: clinical and laboratory lessons learned from the large von Willebrand disease studies. Am J Hematol 2012; 87(Suppl. 1): S4-11.
2. De Wee EM, Sanders YV, Mauser-Bunschoten EP, van der Bom JG, Degenaar-Dujardin ME, Eikenboom J, De Goede-Bolder A, Laros-van Gorkom BA, Meijer K, Hamulyak K, Nijziel MR, Fijnvandraat K, Leebeek FW, for the WiN Study Group. Determinants of bleeding phenotype in adult patients with moderate or severe von Willebrand disease. Thromb Haemost 2012; 108: 683-92.
3. Sadler JE, Budde U, Eikenboom JC, Favaloro EJ, Hill FG, Holmberg L, Ingerslev J, Lee CA, Lillicrap D, Mannucci PM, Mazurier C, Meyer D, Nichols WL, Nishino M, Peake IR, Rodeghiero F, Schneppenheim R, Ruggeri ZM, Srivastava A, Montgomery RR, et al. Update on the pathophysiology and classification of von Willebrand disease: a report of the Subcommittee on von Willebrand Factor. J Thromb Haemost 2006; 4: 2103-14.
4. Goodeve A, Eikenboom J, Castaman G, Rodeghiero F, Federici AB, Batlle J, Meyer D, Mazurier C, Goudemand J, Schneppenheim R, Budde U, Ingerslev J, Habart D, Vorlova Z, Holmberg L, Lethagen S, Pasi J, Hill F, Hashemi Soteh M, Baronciani L, et al. Phenotype and genotype of a cohort of families historically diagnosed with type 1 von Willebrand disease in the European study, Molecular and Clinical Markers for the Diagnosis and Management of Type 1 von Willebrand Disease (MCMDM-1VWD). Blood 2007; 109: 112-21.
5. Robertson JD, Yenson PR, Rand ML, Blanchette VS, Carcao MD, Notley C, Lillicrap D, James PD. Expanded phenotype-genotype correlations in a pediatric population with type 1 von Willebrand disease. J Thromb Haemost 2011; 9: 1752-60.
6. Eikenboom J, van Marion V, Putter H, Goodeve A, Rodeghiero F, Castaman G, Federici AB, Batlle J, Meyer D, Mazurier C, Goudemand J, Schneppenheim R, Budde U, Ingerslev J, Vorlova Z, Habart D, Holmberg L, Lethagen S, Pasi J, Hill F, et al. Linkage analysis in families diagnosed with type 1 von Willebrand disease in the European study, Molecular and Clinical Markers for the Diagnosis and Management of Type 1 VWD. J Thromb Haemost 2006; 4: 774-82.
7. James PD, Notley C, Hegadorn C, Leggo J, Tuttle A, Tinlin S, Brown C, Andrews C, Labelle A, Chirinian Y, O'Brien L, Othman M, Rivard G, Rapson D, Hough C, Lillicrap D. The mutational spectrum of type 1 von Willebrand disease: results from a Canadian cohort study. Blood 2007; 109: 145-54.
8. Smith NL, Chen MH, Dehghan A, Strachan DP, Basu S, Soranzo N, Hayward C, Rudan I, Sabater-Lleal M, Bis JC, de Maat MP, Rumley A, Kong X, Yang Q, Williams FM, Vitart V, Campbell H, Malarstig A, Wiggins KL, van Duijn CM, et al. Novel associations of multiple genetic loci with plasma levels of factor VII, factor VIII, and von Willebrand factor: the CHARGE (Cohorts for Heart and Aging Research in Genome Epidemiology) Consortium. Circulation 2010; 121: 1382-92.
9. van Loon JE. Genome-wide assocation studies identify genetic loci for low von Willebrand factor levels. In: Genetic Determinants of von Willebrand Factor and the Risk of Cardiovascular Disease. PhD Thesis, Schiedam, the Netherlands, 2012; 105-21.
10. Widberg CH, Bryant NJ, Girotti M, Rea S, James DE. Tomosyn interacts with the t-SNAREs syntaxin4 and SNAP23 and plays a role in insulin-stimulated GLUT4 translocation. J Biol Chem 2003; 278: 35093-101.
11. Lowenstein CJ, Morrell CN, Yamakuchi M. Regulation of Weibel-Palade body exocytosis. Trends Cardiovasc Med 2005; 15: 302-8.
12. van Loon JE, Leebeek FW, Deckers JW, Dippel DW, Poldermans D, Strachan DP, Tang W, O'Donnell CJ, Smith NL, de Maat MP. Effect of genetic variations in syntaxin-binding protein-5 and syntaxin-2 on von Willebrand factor concentration and cardiovascular risk. Circ Cardiovasc Genet 2010; 3: 507-12.
13. Rydz N, Swystun LL, Notley C, Paterson AD, Riches JJ, Sponagle K, Boonyawat B, Montgomery RR, James PD, Lillicrap D. The C-type lectin receptor CLEC4M binds, internalizes, and clears von Willebrand factor and contributes to the variation in plasma von Willebrand factor levels. Blood 2013; 121: 5228-37.
14. Harris EN, Weigel PH. The ligand-binding profile of HARE: hyaluronan and chondroitin sulfates A, C, and D bind to overlapping sites distinct from the sites for heparin, acetylated low-density lipoprotein, dermatan sulfate, and CS-E. Glycobiology 2008; 18: 638-48.
15. Gallinaro L, Cattini MG, Sztukowska M, Padrini R, Sartorello F, Pontara E, Bertomoro A, Daidone V, Pagnan A, Casonato A. A shorter von Willebrand factor survival in O blood group subjects explains how ABO determinants influence plasma von Willebrand factor. Blood 2008; 111: 3540-5.
16. Jiang Y, Oliver P, Davies KE, Platt N. Identification and characterization of murine SCARA5, a novel class A scavenger receptor that is expressed by populations of epithelial cells. J Biol Chem 2006; 281: 11834-45.
17. Morange PE, Saut N, Antoni G, Emmerich J, Tregouet DA. Impact on venous thrombosis risk of newly discovered gene variants associated with FVIII and VWF plasma levels. J Thromb Haemost 2011; 9: 229-31.
18. van Loon JE, Sanders YV, de Wee EM, Kruip MJ, de Maat MP, Leebeek FW. Effect of genetic variation in STXBP5 and STX2 on von Willebrand factor and bleeding phenotype in type 1 von Willebrand disease patients. PLoS One 2012; 7: e40624.
19. Sanders YV, Eikenboom J, de Wee EM, van der Bom JG, Cnossen MH, Degenaar-Dujardin ME, Fijnvandraat K, Kamphuisen PW, van Gorkom BA, Meijer K, Mauser-Bunschoten EP, Leebeek FW, WiN Study Group. Reduced prevalence of arterial thrombosis in von Willebrand disease. J Thromb Haemost 2013; 11: 845-54.
20. De Wee EM, Knol HM, Mauser-Bunschoten EP, van der Bom JG, Eikenboom JC, Fijnvandraat K, De Goede-Bolder A, Laros-van Gorkom B, Ypma PF, Zweegman S, Meijer K, Leebeek FW. Gynaecological and obstetric bleeding in moderate and severe von Willebrand disease. Thromb Haemost 2011; 106: 885-92.
21. de Wee EM, Mauser-Bunschoten EP, van der Bom JG, Degenaar-Dujardin ME, Eikenboom HCJ, Fijnvandraat K, de Goede-Bolder A, Laros-van Gorkom BAP, Meijer K, Raat H, Leebeek FWG, for the WiN Study Group. Health-related quality of life among adult patients with moderate and severe von Willebrand disease. J Thromb Haemost 2010; 8: 1492-9.
22. Sanders YV, Giezenaar MA, Laros-van Gorkom BA, Meijer K, van der Bom JG, Cnossen MH, Nijziel MR, Ypma PF, Fijnvandraat K, Eikenboom J, Mauser-Bunschoten EP, Leebeek FW, WiN Study Group. von Willebrand disease and aging: an evolving phenotype. J Thromb Haemost 2014; 12: 1066-75.
23. Tosetto A, Rodeghiero F, Castaman G, Goodeve A, Federici AB, Batlle J, Meyer D, Fressinaud E, Mazurier C, Goudemand J, Eikenboom J, Schneppenheim R, Budde U, Ingerslev J, Vorlova Z, Habart D, Holmberg L, Lethagen S, Pasi J, Hill F, et al. A quantitative analysis of bleeding symptoms in type 1 von Willebrand disease: results from a multicenter European study (MCMDM-1 VWD). J Thromb Haemost 2006; 4: 766-73.
24. Tosetto A, Castaman G, Rodeghiero F. Bleeding scores in inherited bleeding disorders: clinical or research tools? Haemophilia 2008; 14: 415-22.
25. Landsteiner K. On agglutination of normal human blood. Transfusion 1961; 1: 5-8.
26. Pare G, Chasman DI, Kellogg M, Zee RY, Rifai N, Badola S, Miletich JP, Ridker PM. Novel association of ABO histo-blood group antigen with soluble ICAM-1: results of a genome-wide association study of 6, 578 women. PLoS Genet 2008; 4: e1000118.
27. Miller SA, Dykes DD, Polesky HF. A simple salting out procedure for extracting DNA from human nucleated cells. Nucleic Acids Res 1988; 16: 1215.
28. Barrett JC, Fry B, Maller J, Daly MJ. Haploview: analysis and visualization of LD and haplotype maps. Bioinformatics 2005; 21: 263-5.
29. van Schie MC, Wieberdink RG, Koudstaal PJ, Hofman A, Ikram MA, Witteman JC, Breteler MM, Leebeek FW, De Maat MP. Genetic determinants of von Willebrand factor plasma levels and the risk of stroke: the Rotterdam Study. J Thromb Haemost 2012; 10: 550-6.
30. van Breevoort D, Snijders AP, Hellen N, Weckhuysen S, van Hooren KW, Eikenboom J, Valentijn K, Fernandez-Borja M, Ceulemans B, De Jonghe P, Voorberg J, Hannah M, Carter T, Bierings R. STXBP1 promotes Weibel-Palade body exocytosis through its interaction with the Rab27A effector Slp4-a. Blood 2014; 123: 3185-94.
31. Gill JC, Endres-Brooks J, Bauer PJ, Marks WJ Jr, Montgomery RR. The effect of ABO blood group on the diagnosis of von Willebrand disease. Blood 1987; 69: 1691-5.
32. Dahabreh IJ, Kent DM. Index event bias as an explanation for the paradoxes of recurrence risk research. JAMA 2011; 305: 822-3.
33. Bowman M, Mundell G, Grabell J, Hopman WM, Rapson D, Lillicrap D, James P. Generation and validation of the condensed MCMDM-1VWD bleeding questionnaire for von Willebrand disease. J Thromb Haemost 2008; 6: 2062-6.